Lymphoma

In the DBL3001 trial, the combination of ibrutinib and R-CHOP was not superior to treatment with R-CHOP alone.

In addition to significant improvements in 5-year OS and PFS with maintenance rituximab, there was a trend toward an association between maintenance and reduced transformation risk.

TROG 99.03 constitutes “the only high level evidence currently available to guide decision making for this group of patients,” says investigator Michael MacManus.

There may be prophylactic benefit from using lenalidomide, an orally bioavailable CNS-penetrating agent, combined with R-CHOP in the upfront setting.

The OS benefit associated with standard treatment diminished in patients older than 80 with high comorbidity scores, but other age groups fared better.

De-escalated treatment may be possible in patients with advanced HL who reach a metabolic response after only 2 cycles of escalated BEACOPP.

Efficacy of lenalidomide plus rituximab was similar to chemotherapy induction in previously untreated symptomatic FL, with a better safety profile.

In the DAWN trial, however, investigators said, “some patients experienced prolonged remission durations and symptom relief with no new safety signals.”

AEs were more common in patients assigned to obinutuzumab compared with rituximab; however, baseline characteristics differed between treatment arms.

Here we review current prognostic models, risk factors, and prophylaxis methods to provide a practical approach to preventing CNS relapse in patients with DLBCL.

Polatuzumab vedotin administered with bendamustine and rituximab significantly improved PET-based CR rates, PFS, and OS in DLBCL but not FL.

In TRANSCEND NHL 001, the CD19-directed 4-1BB CAR T-cell product lisocabtagene maraleucel yielded durable responses in heavily pretreated R/R DLBCL.

While HCT is an important benefit for FL patients, the optimal approach remains up for debate.

The approval includes adults with R/R DLBCL after two or more lines of prior systemic therapy, high-grade B-cell lymphoma, and DLBCL arising from FL.

“The core message is that DLBCL can no longer be viewed as a single disease,” explained senior author Dr. Louis M. Staudt, Director of NCI’s Center for Cancer Genomics.

In the DUO and DYNAMO trials, duvelisib improved clinical responses in patients with R/R CLL/SLL and FL, respectively.

Pooled data show PET imaging of metabolic tumor burden at diagnosis helps identify patients most at risk of FL recurrence.

The FDA has approved brentuximab vedotin (Adcetris) to treat adults with previously untreated stage III or IV cHL, in combination with chemotherapy.

Follicular large cleaved cell lymphoma is frequently misclassified, according to researchers.

In this large population-based, case-control study, having ever used a statin was linked to lower risk of total NHL and certain NHL subtypes, including DLBCL.

BET inhibitors CPI-1205 and CPI-0610 have shown promise in two phase I trials in DLBCL and other lymphomas, investigators at TAT 2018 reported.

Recent FDA approval of front-line brentuximab vedotin with chemotherapy in patients with stage III/IV Hodgkin lymphoma offers the first new treatment for this disease in over 40 years.

Umbralisib, a dual inhibitor of PI3Kδ and casein kinase-1Ɛ, was well tolerated and showed early signs of clinical activity in a phase I lymphoma study.

In this interview, Dr. Frederick Locke discusses the promise of CAR T-cell therapy for lymphomas, and how this gene therapy could offer hope for patients who don't respond to standard treatments.

Researchers report that PD-1/PD-L1 monoclonal blocking antibody allows T cells to remain active and fight malignant evolution, subsequently preventing tumor resistance.